(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID Basic information
- Product Name:
- (+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID
- Synonyms:
-
- CAY10471
- (+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID
- CAY10471, CRTH2/DP2 antagonist
- 2-[3-[(4-fluorophenyl)sulfonyl-methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]acetic acid)
- CAS:
- 627865-18-3
- MF:
- C21H21FN2O4S
- MW:
- 416.47
- Mol File:
- 627865-18-3.mol
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:5): 0.5 mg/ml; Ethanol: 15 mg/ml
- form
- A crystalline solid
- color
- White to off-white
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACID Usage And Synthesis
Uses
CAY10471 (TM30089) is a potent, selective, and orally active prostaglandin D2 receptor CRTH2?antagonist. CAY10471 attenuates the progression of tubulointerstitial fibrosis and chronic contact hypersensitivity (CHS) in animal model[1][2][3].
in vivo
CAY10471 (oral treatment; 2 mg/kg; challenged on day 22 or over 10 consecutive days) shows a diminished inflammation in chronic contact hypersensitivity (CHS) and IgE-CAI model. It blocks CRTH2 partly, but significantly suppresses inflammation in mice[2].CAY10471 (oral adminstration; 20 mg/kg; twice daily; beginning 3/4/5 days before UUO) significantly attenuates interstitial collagen deposition in the cortex when compared with the vehicle (8.40% versus 14.85%). Oral administration from 3 days after UUO also significantly attenuates interstitial collagen deposition in the cortex compared with vehicle (9.63% versus 14.44%). However, oral administration beginning 5 days after UUO has little effect on interstitial collagen deposition in the cortex when compared with vehicle (14.61% versus 15.09%). Unilateral ureteral obstruction (UUO)[3].
| Animal Model: | Balb/c mice, DP?/? mice, CRTH2?/? mice[2] |
| Dosage: | 2 mg/kg |
| Administration: | Oral treatment; once daily; challenged on day 22 or over 10 consecutive days |
| Result: | Significantly suppressed both CHS and IgE-CAI inflammatory responses. |
| Animal Model: | C57BL/6 mice[3] |
| Dosage: | 20 mg/kg |
| Administration: | Oral treatment; twice daily; beginning 3/4/5 days before UUO |
| Result: | Slowed the progression of renal fibrosis in the obstructed kidneys. |
IC 50
CRTH2
References
[1] Hatanaka M, et al. 15d-prostaglandin J2 enhancement of nerve growth factor-induced neurite outgrowth is blocked by the chemoattractant receptor- homologous molecule expressed on T-helper type 2 cells (CRTH2)?antagonist?CAY10471 in PC12 cells. J Pharmacol Sci.?2010;113(1):89-93. Epub 2010 Apr 16. DOI:10.1254/jphs.10001sc
[2] Matsushima Y, et al. Distinct roles of prostaglandin D2 receptors in chronic skin inflammation.Mol Immunol. 2011 Oct;49(1-2):304-10. DOI:10.1016/j.molimm.2011.08.023
[3] Ito H, et al. PGD2-CRTH2?pathway promotes tubulointerstitial fibrosis.J Am Soc Nephrol.?2012 Nov;23(11):1797-809. DOI:10.1681/ASN.2012020126
(+)-3-[[(4-FLUOROPHENYL)SULFONYL]METHYLAMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-ACETIC ACIDSupplier
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 16314854226
- info@bocsci.com
- Tel
- 18818260767
- sales@chemegen.com
- Tel
- 027-59626688 18771149750
- sales@amyjet.com
- Tel
- 0513-66337626 18051384581
- sales@chemhifuture.com